inorganic sulfate(S0 )and m o s t s u l f u r c o n t a i n i n g a m i n o acids are k n o w n t o bd e l e v a t e d in uremia(U1. Taurine(Tau)is i m p o r t a n t f o r the regulation o f neuromuscular functions, especially in the heart, where i t comprises 75% o f a l l amino acids. In o r d e r t o i n v e s t i g a t e the r o l e o f S 0 4 , a n d T a u in U bilateral nephrectomy(NX) was performed I n 38 rats. SO a n d Tau c o n c e n t r a t i o n s i n p l a s m a a n d v a r i o u s o r g a n 4 were d e t e r m i n e d 12,24 a n d 48 hrs a f t e r N X and c o m p a r e d t o sham o p e r a t e d a n d normal rats. In NX rats mean SO r o s e l i n e a r l y in plasma(0.9 t o 7.8 mmol/l) a n d l e s s f n liver(0.6 t o 3.2 mmol/g w e t wt.). The i n c r e a s e was onl y x 2.0 in s k e l e t a l m u s c l e a n d x 1.5 i n brain. A close c o r r e l a t i o n w a s found between p l a s m a SO4 a n d creatinine(r=0.92).
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T h e p l a s m a l e v e l s o f inorganic sulfate(S0 )and m o s t s u l f u r c o n t a i n i n g a m i n o acids are k n o w n t o bd e l e v a t e d in uremia(U1. Taurine(Tau)is i m p o r t a n t f o r the regulation o f neuromuscular functions, especially in the heart, where i t comprises 75% o f a l l amino acids. In o r d e r t o i n v e s t i g a t e the r o l e o f S 0 4 , a n d T a u in U bilateral nephrectomy(NX) was performed I n 38 rats. SO a n d Tau c o n c e n t r a t i o n s i n p l a s m a a n d v a r i o u s o r g a n 4 were d e t e r m i n e d 12,24 a n d 48 hrs a f t e r N X and c o m p a r e d t o sham o p e r a t e d a n d normal rats. In NX rats mean SO r o s e l i n e a r l y in plasma(0.9 t o 7.8 mmol/l) a n d l e s s f n liver(0.6 t o 3.2 mmol/g w e t wt.). The i n c r e a s e was onl y x 2.0 in s k e l e t a l m u s c l e a n d x 1.5 i n brain. A close c o r r e l a t i o n w a s found between p l a s m a SO4 a n d creatinine(r=0.92).
T a u l e v e l s increased i n p l a s m a f r o m 0.2 t o 0.5 bmol/ml a n d in liver f r o m 2.0 t o 7.2 pmol/g w e t wt., b u t decreased i n t h e h e a r t f r o m 26.0 t o 21.0 bmol/g w e t wt.(p<0.01) a n d remained c o n s t a n t in skel e t a l m u s c l e a n d brain.
In c o n c l u s i o n , intracellular c h a n g e s o f SO and Tau are n o t reflected by p l a s m a levels. The a p b a r e n t efflux of Tau f r o m the h e a r t o f N X rats m i g h t be r e l a t e d t o t h e p a t h o g e n e s i s o f u r e m i c h e a r t disease.
PHARMACOLOGIC AGENTS

INTRAVENOUS METHYLPREDNISOLONE IN THE TREATMENT OF
76 STEROID RESPONSIVE NEPHROTIC SYNDmME. Kennedy, T.L.
Rasoulpour, M. 6 McLean, R.H., Division of Pediatric Nephroloyy, University of Connecticut Health Center, Farmington Connecticut, 06032, U.S.A. Six children in relapse with steriod responsive nephrotic syndrom recelved 3 doses of intravenous methylprednisolone (30mg/kg) on alternatr days. The 6 children received a total of 9 courses of methylprednisolone and there were no adverse effects. Each course was followed immediately by prednisone therapy (Img/ky) on alternate days. Five were frequent relapsers and the sixth had many recurrences over 15 years. All were males witha mean age of 4.5 years at onset and 9.1 years at the tlme of "pulse" therapy. All had normal renal function. Renal biopsies showed mild mesangial proliferation in 3, focal sclerosis in 1 and minimal change in 1. Four subsequently achieved sustained remissions after chlorambucil therapy and the remaining 2 continued to have occasional relapses. Following 8 courses, a remission occurred in 5 to 15 days (mean 7 days) and in the ninth a remission occurred after 46 days. During 11 previous relapses the interval to remission using oral prednisone was 5 to 21 days (mean o f 11 days). Prior to "pulse" therapy the mean interval between relapses was 131 days (range 30 I o 260 <l.sys) : following " l l u l u . . " t l 1 r . l ally, L l l c mcart InLurval was 13U days (range 23 to 420 days). We coriclude that intravenous methylprednisolone "pulse" therapy In steroid responsivr nephrotic syndrome of childhood can induce a remission which 1s similar with respect to the time of onset and the duration of the remission achieved with oral prednlsone therapy.
CHLORMETHINE (C) IN NEPHROSIS (N)
. LENOIR G. , 177 KLEINKNECHT c., GUESRY P., BROYER M. Hdpital des Enfants-Malades. PARIS. FRANCE.
C. was used In 18 Steroid-Resistant (SR) N and in 27
Steroid-Sensitive (SS)N. Two regimens were used : In the former a total dose of 0.8tol/nlg/kg was given alone using 12 IV injectlons over one month. In the latter d total dose of 0.8 my/kg was qlven over two periods of 4 days separated by one month. and was associated with Prednisone (2 mg/kg/day) and antl-emetlc agents. In SPN, only one patient remitted, whereas 2 had a translent ( 2 weeks) and one a partial remission. The others were un changed. SSN were all steroid dependent and 13/27 had severe steroid toxlclty slgns. C. was glven 0.5 to 1 1 years after onset. A rei.lission was obtained In all but two patients treated with the first regimen. Remission lastrd less than one year In 10, 1 to 2 -years ~n 5. In the remainder, follow-up was less than 2 years, except for 4 children : one had a relapse 4 years later, and 3 had sustained remission 2.2 1/2 and 1 1 years after therapy. Of the -16 patleilts wl~o relapsed, G received other nltrogen mustards and 1 0 were controlled uslny nor1 toxlc doses of alternate-day Prednlsone therapy. Sidt, effects were leucopenia (20'h) including pancytopenia in 3 chlldrrn and rlastrolntestlnal disorders (50%). Only one patient was studled in adulthood and had a r~ormal spermcount. In conclusion : C. was 111efft~ct~ve ~n SRN, orld resulLed mainly In short remissions In SSN. In SSN howcver. C. when associated with Prednisone sremsi~*!~t~f 1~1 . 1 1 In decreaslnij the dose of Prednisone requlrrd to maintaLr1 remlsslor!.
A CONTROLLED THERAPEUTIC TRIAL OF CYCLOPHOSPHAMIDE
PLUS PREDNISONE VERSUS PREDNISONE ALONE IN CHILD-REN WITH FOCAL SEGMENTAL GLOMERULOSCLEROSIS (FSGS).
A preliminary report of the International Study of Kidney Disease in Children.
41 children with nephrotic syndrome having FSGS histologically were randomly allocated to one of tw therapeutic regimens. Both groups received Prednisone 40 mg/mq on alternate days for 12 months either alone (group A) or together with Cyclophosphamide 2.5 mg/kg daily for the first 90 days of the year (group 8).
Heavy proteinuria initially present in all children disappe2red in 5/16 (31.3% in group A and 9/23 (39.1%) in group B.
(X 0.03 p:NS). Serum albumin concentrations returned to normal in all 12 proteinuria-free patients for whom there was dataand also in 4/25 patients in both groups (2 in each) whose proteinuria persisted. Deterioration of renal function occu red in 4/16 (25%) in group A and 12/25 (482) in group B (XI 1.31 p:NS).
In 16 children with deteriorating function, data on proteinuria were available in 14 -all but one had persisting proteinuria. Other data show a tendency for functional deterioration to be commoner in older females with a longer duration of disease prior to entry in the study.
We conclude that while the disease runs a variable course there is no evidence from this study that either therapeutic regimen was superior to the other. The natural history of the condition in the absence of therapy is not known. 50.7 ; 7.0 70.6 ; 6.4* 82.0 ; 7.7* 0th r 6 18.2 f 2.5 38.6 t 7.5* 73.7 f 10.9* 'PAH increased with pulse therapy in a1 groups, increasing 1 from 307 t 62.2 to 644 t 81.3 ml/min/1.73m in HSP patients (p<.02). Protein excretion decreased from pre-treatment 3.7 f 1.0 to 1.4 * 0.4 g/day post-treatment. Side effects of pulse therapy were few. hypertension being seen only in patients with pre-existing hypertension. Improvements in GFR following pulses were maintained in 25 patients treated subsequently with oral Predniaone-initial dose 2 mglkp, with subseqlrent ntepwise redoctions. Of tlie four patients failing to maintain improvement after pulses, three were treated late in the course of their disease.
HIGH DOSE INTRAVENOUS METHYLPREDNISOLONE BOLUS THER-
APY (lIPuLsEsu) IN S E E R E PRoLIPERATIm
Theae observations support our preliminary findings (J. Peds, 88,307,1976) 
